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Polyglutamine diseasePolyglutamine diseases are a family of inherited neurodegenerative diseases caused by the expansion of CAG re-
peats within the coding region of target genes. Still the mechanism(s) by which polyglutamine proteins are
ubiquitinated and degraded remains obscure. Here, for the ﬁrst time, we demonstrate that Mahogunin 21 ring
ﬁnger 1 E3 ubiquitin protein ligase is depleted in cells that express expanded-polyglutamine proteins. MGRN1
co-immunoprecipitates with expanded-polyglutamine huntingtin and ataxin-3 proteins. Furthermore, we
show that MGRN1 is predominantly colocalized and recruits with polyglutamine aggregates in both cellular
and transgenic mouse models. Finally, we demonstrate that the partial depletion of MGRN1 increases the rate
of aggregate formation and cell death,whereas the overexpression ofMGRN1 reduces the frequency of aggregate
formation and provides cytoprotection against polyglutamine-induced proteotoxicity. These observations sug-
gest that stimulating the activity of MGRN1 ubiquitin ligase might be a potential therapeutic target to eliminate
the cytotoxic threat in polyglutamine diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
A striking clinical hallmark of many neurodegenerative diseases is
the presence of ubiquitin-positive intracellular inclusions formed by
the aggregation of non-native neurotoxic proteins [1–3]. Numerous
neurodegenerative diseases are caused by trinucleotide repeats, and
polyglutamine diseases are caused by a (CAG)n expansion within the
coding region of the responsible gene. Polyglutamine diseases such as
Huntington's disease (HD), spinocerebellar ataxias (types 1, 2, 3, 6, 7
and 17) and X-linked spinal bulbar muscular atrophy (SBMA) are
most likely caused by the neuronal dysfunction or neuronal cell death
that results as the lengths of the glutamine stretches/repeats increase;
early disease onset and the accumulation of intracellular aggregates
are strongly linked with increased polyglutamine tract length [4–6].4; Baf, baﬁlomycin; BMP,
ed autophagy; CQ, chloroquine;
terminus; IB, inclusion bodies;
RN1, mahogunin ring ﬁnger-1;
m bromide; NEDD4, neural pre-
rotein 4; PrP, prion protein; PD,
1; RING, really interesting new
ality controlThe question of whether the molecular pathology that underlies
polyglutamine disease is caused by a gain or a loss of function is contro-
versial. However, the formation of intraneuronal aggregates and the de-
position of inclusion bodies represent a failure of the cellular protein
quality control mechanism (QC). Currently, there are no known treat-
ments that effectively prevent or eliminate aggregate formation in
polyglutamine diseases. The ubiquitin proteasome system and the au-
tophagy pathway are two molecular mechanisms responsible for elim-
inatingmisfolded or damaged proteins in the cell, and the failure of both
of these mechanisms leads to neurodegeneration [7,8]. Existing studies
suggest that various chaperones, E3 ubiquitin ligases and other compo-
nents of the proteasomal and autophagy degradation pathways are in-
volved in the recognition and clearance of ubiquitin-positive
intracellular aggregates [9–13].
Studies suggest that a massive accumulation of misfolded proteins
impairs proteasome function, e.g., the accumulation of expanded
polyglutamine proteins leads to altered proteasomal function [14–16].
Thus, the molecularmechanism for cell survival under the noxious con-
ditions generated by protein misfolding and the failure of the ubiquitin
proteasome system are of interest. Evidence suggests that under
proteotoxic threat, another misfolded-protein-elimination pathway,
full condition autophagy, maintains the proteostasis in cells [17–19].
In mammalian cells, three different forms of autophagy have been de-
scribed: macroautophagy, chaperone-mediated autophagy (CMA) and
microautophagy [20]. Autophagy promotes the clearance of α-
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teins, and the loss of autophagy causes neurodegenerative disease in
mice [2,21–24].
In the present work, we studied the detailed mechanism of the
ubiquitination and degradation of expanded polyglutamine proteins
by mahogunin ring ﬁnger-1 (MGRN1) E3 ubiquitin ligase through the
autophagy pathway. The aberrant function of MGRN1 leads to late-
onset spongiform neurodegeneration, and MGRN1 also interacts with
cytosolic prion proteins (PrPs) that are linked with neurodegeneration
[25,26]. Here, we report that MGRN1 interacts with expanded
polyglutamineproteins and recruitswith ubiquitin and p62-positive ex-
panded polyglutamine protein aggregates in both cellular and R6/2
transgenic mouse models. Moreover, MGRN1 is involved in the
ubiquitination of expanded polyglutamine proteins; the overexpression
of MGRN1 reduces polyglutamine-mediated cytotoxicity and prevents
polyglutamine protein-induced cell death.2. Materials and methods
2.1. Materials
Baﬁlomycin, 2-mercaptoethanol, TRIzol reagent, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
N6,2′-O-dibutyryladenosine-3′,5′-cyclic monophosphate (dbcAMP)
and all cell culture reagents were obtained from Sigma. Lipofectamine
2000, optiMEM, plasmid pcDNA™ 3.1, ProLong® Gold Antifade Re-
agent, reverse transcription-polymerase chain reaction (RT-PCR) kits,
Zenon®Alexa Fluor® 350 Mouse IgG1 labeling kits and Zenon®Alexa
Fluor® 350 Rabbit IgG labeling kits were obtained from Life Technolo-
gies and Molecular Probes. Mouse monoclonal green ﬂuorescent pro-
tein (GFP) antibody, nitroblue tetrazolium salt (NBT), BCIP (5-bromo-
4-chloro-3-indolyl phosphate, toluidinium salt) and protein G-agarose
beads were obtained from Roche Applied Science. iQ SYBR green
super mix was from BioRad. Horseradish peroxidase-conjugated anti-
rabbit, anti-goat and anti-mouse IgG was purchased from Amersham
Biosciences. Alkaline phosphatase-conjugated anti-goat, anti-rabbit
and anti-mouse IgG was purchased from Vector Laboratories. Anti-
mouse IgG-ﬂuorescein isothiocyanate and IgG-rhodamine and anti-
rabbit IgG-ﬂuorescein isothiocyanate and IgG-rhodamine were pur-
chased from Vector Laboratories. Monoclonal anti-ubiquitin, polyclonal
anti-GFP, polyclonal anti-MGRN1 (SC-160519), and monoclonal anti-
actin- and MGRN1-speciﬁc siRNA oligonucleotides were purchased
from Santa Cruz Biotechnology. Polyclonal anti-MGRN1 (SAB2101478)
and monoclonal-anti-p62/SQSTM1 were purchased from Sigma. Rabbit
polyclonal anti-ubiquitin was purchased from Dako. pEGFP-Hsp70
(Addgene-15215), plasmid pcDNA3-EGFP (Addgene 13031), pcDNA3-
cmyc (Addgene 16011), pEGFP-C1-Ataxin3Q28 (Addgene-22122)
and pEGFP-C1-Ataxin3Q84 (Addgene-22123) were purchased from
Addgene.2.2. Cell culture, transfection and cell viability assay
Cos-7, A549 and 293T cells were maintained in DMEM (Sigma-
Aldrich). All cells were supplemented with 10% heat-inactivated
fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin
and were grown at 37 °C in 5% CO2. For the various experiments, cells
were plated into 6-well, 24-well and 96-well tissue culture plates be-
fore one day of transfection at a subconﬂuent density. Lipofectamine
2000 transfection reagent was used for all transfections, in combination
with various expression vectors that were used according to the manu-
facturers' protocols. The transfection efﬁciency was 80%–90% in all
experiments. Cell viability was determined by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, as described previously
[27].2.3. Co-immunoprecipitation and immunoblotting experiment
Cos-7 cells were transiently transfectedwith normal (ataxin-3(Q28)
and EGFP-HDQ23) and expanded polyglutamine (ataxin-3(Q28) and
EGFP-HDQ74) constructs along with the MGRN1 plasmid. After 24 h,
the cells were washed with PBS and lysed on ice for 30 min with NP-
40 lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% NP-40 and com-
plete protease inhibitor cocktail). The cell lysates were prepared for im-
munoprecipitation by brieﬂy sonicating before centrifugation for
15min at 15,000 ×g at 4 °C. For each immunoprecipitation experiment,
approximately 200 μg of protein in 0.2 ml of NP40 lysis buffer was incu-
bated with 5 μg of primary antibody. The total cell lysate of the
immunoprecipitated samples was separated by SDS-polyacrylamide
gel electrophoresis and processed for immunoblotting as described
elsewhere [28,29]. All primary antibodieswere used at a 1:1000dilution
for immunoblotting except for GFP, which was used at a 1:2000
dilution.
2.4. Immunoﬂuorescence techniques
Cos-7 cells were grown in two-well chamber slides and were tran-
siently transfected with the appropriate plasmids. After transfection
for 48 h, the cells were washed twice with phosphate-buffered saline,
ﬁxed with 4% paraformaldehyde in phosphate-buffered saline for
30 min, permeabilized with 0.5% Triton X-100 in phosphate-buffered
saline for 5 min, washed extensively and then blocked with 5% nonfat
skim milk in Tris-buffered saline-Tween 20 (TBST) [50 mM Tris,
pH 7.5, 0.15MNaCl, 0.05% Tween 20] for 1 h. In some triple-labeling ex-
periments, primary antibodies of p62 and ubiquitin were incubated
with Zenon®Alexa Fluor® kits according to the manufacturer's proto-
col. Primary antibody incubation was carried out overnight at 4 °C.
After incubation, the cells were washed several times with TBST, incu-
bated with rhodamine-conjugated secondary antibody (1:500 dilution)
for 1 h, washed several times and ﬁnally processed for mounting as de-
scribed previously [30]. Mounted slides were observed using a ﬂuores-
cence microscope, and digital images were assembled using Adobe
Photoshop.
2.5. Immunoﬂuorescence staining in R6/2 mouse model of HD
For immunoﬂuorescence staining of MGRN1, ubiquitin and p62 in
the control and transgenic mouse brain sections, parafﬁn-embedded
sections from various brain regions were deparafﬁnized, subjected to
antigen retrieval and then processed for staining as described previous-
ly [27,31]. Appropriate FITC- and rhodamine-conjugated secondary an-
tibodies were used to visualize expression, and all sections were
mounted in ProLong®Gold Antifade Reagent (Life Technologies) before
analysis of expression and colocalization. In each experiment, we used
12-week-old male R6/2 transgenic mice and control male littermates
of same age; the CAG repeat sizes in the R6/2 transgenic mice were
134 CAGQ and 130Q. CAG repeat length of htt for each mouse was rou-
tinely determined by the almost same method described previously
[32] to exclude the deviated repeat samples due to the instability of
CAG repeat. PCR was performed with FAM-labeled primer 31329
(ATGAAGGCCTTC GAGTCCCTCAAGTCCTTC) and primer 33934 (GGCG
GCTGAG GAAGCTGAGGA) followed by capillary electrophoresis with
ABI 3130xl (Applied Biosystems) and analysis with Genescan software
(Applied Biosystems). In immunoﬂuorescence staining experiments
we used 5 μm thick parafﬁn-embedded brain sections. All experiments
involving mice were approved by the Animal Experiment Committee
of the RIKEN Brain Science Institute.
2.6. Degradation assay, aggregate counting and statistical analysis
Cos-7 cells were plated in a 6-well tissue-cultured plate. After 24 h,
the cells were transiently transfected with plasmids for the expanded
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eight hours after transfection, the cellswere chasedwith 15 μg/ml of cy-
cloheximide for the different time periods indicated. Cells were collect-
ed at each time point, and samples were processed for immunoblotting
using the GFP antibody. Expanded polyglutamine aggregate formation
was observed and counted under a ﬂuorescence microscope (∼400
transfected cells in each case). Cells retaining more than one aggregate
were considered to have a single big inclusion. Statistical difference
values are presented as mean± SD. Statistical analysis between groups
and intergroup comparisons were performed by using the Student's t
test, and p b 0.05 indicated statistical signiﬁcance. The cell viability
was determined by the MTT assay as described previously [33].
2.7. Reverse transcriptase (RT) PCR analysis, quantitative real time RT-PCR
analysis and RNA interference (RNAi) experiments
Cells were transfected with normal and expanded polyglutamine
plasmids and we achieved about 80%–90% transfection efﬁciency.
After 48 h of transfection, most of the expanded polyglutamine
transfected cells were positive for aggregate formation and same cells
were used for total RNA isolation with TRIzol reagent. Then semi-
quantitative RT-PCR was carried out with an RT-PCR kit (Life Technolo-
gies). The RT-PCR analysis conditions were the same for both MGRN1
and β-actin: 30 min at 50 °C for reverse transcription of RNA, an initial
denaturation step at 94 °C for 5 min and further cycling through 94 °C
for 30 s denaturation, 55 °C for 45 s annealing, 72 °C for 1min, a ﬁnal ex-
tension step at 72 °C for 5 min and 5 min at 4 °C to cool down the reac-
tion. The cycle numbers were 34 for MGRN1 and 23 for β-actin. The
sequences of the various primers were as follows: MGRN1F, 5′-ATGG
GCTCCATTCTCAGC-3′; MGRN1R, 5′-GTTGCTGTTGTCGCTGTTCT-3′;
ActinF, 5′-TGACGGGGTCACCCACACTGTGCCCATCTA-3′; and ActinR, 5′-
CTAGAAGCATTTGCGGTGGACGATGGAGGG-3′. The quantitative real
time PCR for MGRN1 was performed by using iQ SYBR green super
mix (BioRad) after cDNA synthesis from total RNA isolated from culture
cells using TRIzol reagent. Reactions were normalized with 18S RNA as
internal control and all reactionswere carried out in triplicate with neg-
ative controls lacking the template DNA. The real time PCRs were done
using an iCycler iQ real-time Thermocycler Detection System (Bio-Rad).
MISSION® siRNA Universal Negative Control #1 (SIC001) was pur-
chased from Sigma. MGRN1 siRNA (h): sc-92983 was obtained from
Santa Cruz Biotechnology. Another set of MGRN1 predesigned siRNA
was purchased from Sigma, sequence of MGRN1-siRNA (GGAUGACG
AGCUGAACUUU; AAAGUUCAGCUCGUCAUCC). For RNAi experiments,
EGFP-HDQ74-expressing cells were transiently transfected with either
MGRN1-siRNA or Control-siRNA oligonucleotides according to the
manufacturer's protocol. At various time intervals, as indicated, cell ag-
gregate formation was counted under a ﬂuorescence microscope. Some
cells were collected and processed for RT-PCR and immunoblotting
analysis. For the cell death assay, EGFP-HDQ74-expressing cells were
transfected with MGRN1-siRNA or Control-siRNA oligonucleotides,
and cell viability was measured by MTT assay.
3. Results
3.1. Misfolded and ubiquitinated expanded polyglutamine proteins
dysregulated MGRN1 expression
Protein misfolding promotes the ubiquitination and degradation of
expanded polyglutamine proteins; failure to clear these aggregated
polyglutamine proteins causes neurodegenerative diseases (also re-
ferred to as polyglutamine diseases). To examine the effect of
polyglutamine on endogenous MGRN1 levels, we transfected normal
(ataxin-3(28Q) and EGFP-HDQ23-EGFP-tagged huntingtin exon 1 pro-
tein with 23 polyQ repeats) and expanded polyglutamine (ataxin-
3(84Q) and EGFP-HDQ74-EGFP-tagged huntingtin exon 1 protein with
74 polyQ repeats) into A549 cells, as described elsewhere [34,35].These cells form aggregates when they express polyglutamine proteins
with expanded repeat lengths. We isolated total RNA from GFP-
positive aggregated cells and performed RT-PCR analysis for MGRN1.
To our surprise, a signiﬁcant decrease in MGRN1mRNA levels in the ex-
panded polyglutamine ataxin-3(84Q) (Fig. 1A and C) and EGFP-HDQ74
(Fig. 1B and D) expressing cells was observed. We have noticed approx-
imately a 0.5-fold decrease in MGRN1 mRNA levels in the expanded
polyglutamine expressing cells as compared with control cells
(Fig. 1E). Approximately 50–60% of cells were positive for aggregates
(Fig. 1F and G) and expressed normal or expanded polyglutamine pro-
teins (Fig. 1H and I) 48 h after transfection. Next we tested the endoge-
nous levels of MGRN1 in normal and expanded polyglutamine
expressing cells (Fig. 1J). It is surprising to notice dysregulation in
MGRN1 protein levels. We speculate that this is most likely due to se-
questration of endogenous MGRN1 with expanded polyglutamine
proteins. To conﬁrm this hypothesis we performed ﬁlter trap assay with
cell lysates obtained from expanded polyglutamine expressing cells. As
expected, we observed major association of MGRN1 protein with insolu-
ble aggregates of expanded polyglutamine proteins (Fig. 1K). Based on
the data shown in Fig. 1, we hypothesized that aggregation of expanded
polyglutamine proteins promotes their sequestration and that these
events might compromise MGRN1 protein function in the expanded
polyglutamine-expressing cells. To test this hypothesis,we overexpressed
normal and expanded polyglutamine proteins in cells and performed
immunoblotting analysis using a ubiquitin antibody. As shown in
Fig. 2A and B, approximately N50% of the EGFP-HDQ74 and ataxin-
3(84Q)-expressing cells formed GFP-positive aggregates, and the
huntingtin proteins with 74Q repeats and the ataxin-3 proteins with
84Q repeats were ubiquitinated, whereas the proteins with normal glu-
tamine repeats did not exhibit ubiquitination. To conﬁrm our hypothe-
sis, we used the same samples for an immunoblotting analysis of
MGRN1. We further analyzed dysregulation in the endogenous levels
of MGRN1 protein in cells that expressed ubiquitinated expanded
polyglutamine proteins compared with the cells that expressed non-
ubiquitinated proteins with normal numbers of glutamine repeats
(Fig. 2A and C).
3.2. MGRN1 interacts with the N-terminal of truncated misfolded
huntingtin and ataxin-3 with expanded polyglutamine tracts
Our preliminary results suggested that MGRN1 interacts with the
mutant expanded polyglutamine proteins and that this may be one of
the factors involved in the dysregulation of endogenous MGRN1. We
speculated that a stochastic interaction betweenMGRN1 and expanded
polyglutamine proteins likely leads to a huge depletion of MGRN1 at
the site of localization or function. To conﬁrm this assumption, we
checked the interaction of MGRN1 with expanded polyglutamine
proteins. First, we overexpressed normal (ataxin-3(28Q) and EGFP-
HDQ23) or expanded polyglutamine (ataxin-3(84Q) and EGFP-
HDQ74) constructs in cells. Same set of cells was co-transfected with
the MGRN1 construct as shown in Fig. 2D. MGRN1 was strongly and
speciﬁcally immunoprecipitated with the huntingtin (EGFP-HDQ74)
and ataxin-3(84Q) compared with the huntingtin (EGFP-HDQ23) and
ataxin-3(28Q). Fig. 2E shows the same samples as in Fig. 2D respective-
ly, probed with anti-GFP. We performed a detailed immunoprecipita-
tion study using different control experiments to conﬁrm the strong
interaction ofMGRN1with the N-terminals of expanded polyglutamine
huntingtin and ataxin-3 proteins. We further transfected normal and
expanded polyglutamine constructs of the N-terminals of huntingtin
or ataxin-3 proteins. Cell lysates were immunoprecipitated with beads
only (control) (Fig. 2F) and normal IgG (Fig. 2G and H), and the blots
were probed with anti-MGRN1 and anti-GFP antibodies as indicated
in Fig. 2F, G and H. To further conﬁrm the interaction of MGRN1 and ex-
panded polyglutamine proteins, we pulled the cell lysates withMGRN1
antibody and blots were processed with anti-GFP (Fig. 2I) and for the
control experiment only the GFP expressed cell lysates were used to
Fig. 1.MGRN1 dysregulation in expanded polyglutamine-expressing cells. (A–B) A549 cells were transfected with ataxin-3 (A) or EGFP-HD (B) normal and polyglutamine-expanded ex-
pression plasmids as indicated. After 48 h, total RNAwas isolated from the cells andprocessed for RT-PCR analysis usingMGRN1 andβ-actin primers. (C–D) Thebar diagram represents the
quantitation of theMGRN1 band intensities shown in A and B. Datawere collected from three independent experiments using NIH image analysis software and normalized to the levels of
β-actin. Values are the mean ± SD. *, p b 0.05 compared with ataxin-3(Q28)- (C) and EGFP-HDQ23- (D) expressing cells. (E) Cells were transiently ataxin or EGFP-HD normal and
polyglutamine-expanded expression plasmids including control (pcDNA) plasmid. After 48 h, quantitation ofMGRN1mRNA levels using quantitative real time RT-PCR in the experiment.
(F–G) Aggregate formation in ataxin-3(Q84)- (F) and EGFP-HDQ74- (G) expressing cells. (H–I) The same cells were subjected to immunoblotting analysis using GFP and actin antibodies.
(J–K) Cellswere co-transfected as described abovewith ataxin-3-GFP fusion normal (ataxin-3(Q28)) and expanded polyglutamine (ataxin-3(Q84)) and EGFP-HD (normal (EGFP-HDQ23)
and polyglutamine-expanded (EGFP-HDQ74)) constructs. Forty-eight hours after transfection, the cells were collected and processed for immunoblotting withMGRN1and actin antibod-
ies (J). Some cells were cotransfected Myc-MGRN1 plasmid. Same cell lysates were processed for ﬁlter-trap analysis by probing with anti-GFP, anti-MGRN1 and anti-Myc antibodies (K).
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with the GFP antibody (Fig. 2J). These results conﬁrmed our ﬁnding
that MGRN1 strongly interacts with the N-terminals of huntingtin and
ataxin-3 proteins with expanded polyglutamine tracts.
3.3. Association and recruitment of MGRN1with polyglutamine aggregates
To examine whether the subcellular localization of endogenous
MGRN1 is affected by polyglutamine aggregates, we transfected normal
and expanded polyglutamine protein huntingtin (EGFP-HDQ23
(Fig. 3A) and EGFP-HDQ74) (Fig. 3B) and ataxin-3 (ataxin-3(28Q)
(Fig. 3E) and ataxin-3(84Q)) (Fig. 3F) constructs in cells. Aftertransfection, cells were subjected to immunoﬂuorescence staining
using MGRN1 antibody. Endogenous MGRN1 was recruited with the
huntingtin and ataxin-3 expanded polyglutamine aggregates in cells
as shown in Fig. 3. Next, we further co-transfected huntingtin (EGFP-
HDQ23 and EGFP-HDQ74) and ataxin-3 (ataxin-3(28Q) and ataxin-
3(84Q)) constructs with theMGRN1 plasmid. After 48 h of transfection,
cells were subjected to immunoﬂuorescence experiments using the
anti-MGRN1 antibody.MGRN1was localized to the cytoplasmwith par-
tial or diffuse staining in the nucleus of cells expressing normal numbers
of glutamine repeats, shown in Fig. 3C (EGFP-HDQ23), and Fig. 3G
(ataxin-3(28Q)). However, MGRN1 was co-localized and associated
with the aggregates of proteins with expanded polyglutamine repeats
Fig. 2. Ubiquitination of expanded polyglutamine proteins depletes the endogenous level of MGRN1 protein and interaction of MGRN1 with soluble misfolded normal and expanded
polyglutamine proteins. (A) Ataxin-3 normal (ataxin-3(Q28)) and expanded polyglutamine (ataxin-3(Q84)) and EGFP-HD (normal (EGFP-HDQ23) and polyglutamine-expanded
(EGFP-HDQ74)) plasmids were transiently transfected in 293T cells; 48 h after transfection, the cells were subjected to immunoblotting analysis using ubiquitin, GFP, MGRN1 and
actin antibodies. (B) Aggregate formation in expanded polyglutamine-expressing cells transfected with (ataxin-3(Q84) and EGFP-HDQ74) constructs. Arrows indicate the formation of
aggregates in the expanded polyglutamine expressing cells. (C) Quantiﬁcation of endogenousMGRN1 levels collected from three independent experiments using NIH Image analysis soft-
ware. Data were normalized using actin. Values are themean± SD. *p b 0.05with respect to cells expressing proteins with normal numbers of glutamine repeats. (D–E) Transfection was
used to overexpress Myc-MGRN1 and normal (EGFP-HDQ23) and polyglutamine-expanded (EGFP-HDQ74) and ataxin-3 normal (ataxin-3(Q28)) and expanded polyglutamine (ataxin-
3(Q84)) constructs in Cos-7 cells. After 48 h of transfection, the cell lysates were processed for immunoprecipitation (IP) with a GFP antibody. Blots were sequentially probed with anti-
MGRN1 (D) and anti-GFP (E). (F) Cell lysates were collected from ataxin-3 and EGFP-HD normal and expanded polyglutamine-expressing cells and processed for IP by beads alone
(control-IP) and blots were developed by anti-MGRN1. (G–H) As described above some cell lysates were used immunoprecipitation (IP) with normal IgG and blots were probed with
anti-MGRN1 (G) and anti-GFP antibodies (H). (I) Cells were transfectedwith normal (EGFP-HDQ23) and polyglutamine-expanded (EGFP-HDQ74) constructs and lysates were processed
for IP by anti-MGRN1 and blots were developed with anti-GFP. (J) Cells were transfected with only GFP expressing construct and lysates were processed for IP with MGRN1antibody and
blot was developed with GFP antibody. Immunoprecipitants were subject to immunoblotting analysis with the indicated antibodies.
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Control experiment (without secondary antibody) for recruitments of
MGRN1 with expanded polyglutamine aggregates was performed
with EGFP-HDQ23 and EGFP-HDQ74 expressing cells (Supplementary
Fig. S1). To further conﬁrm that the polyglutamine aggregates are posi-
tive for MGRN1, we performed triple-immunoﬂuorescence staining. As
shown in Fig. 4A, MGRN1 was present in the cytoplasm and had a dif-
fuse localization or staining pattern with p62 and ubiquitin in EGFP-
HDQ23-expressing cells with a normal number of glutamine repeats.
Strikingly, MGRN1 recruits and co-localizes with p62 and ubiquitin
double-positive aggregates of expanded polyglutamine proteins
(Fig. 4A and B, lower panel). These results indicate a strong and speciﬁc
interaction between MGRN1 and misfolded-expanded polyglutamine
proteins or their aggregates.3.4. Recruitment and co-localization ofMGRN1with p62 and ubiquitin into
neuronal aggregates of mutant huntingtin in the brains of R6/2 transgenic
mice
To conﬁrm our current ﬁnding that MGRN1 interacts and associates
with p62 and ubiquitin polyglutamine aggregates in cellularmodels, we
examined the recruitment and co-localization of MGRN1 in the R6/2
transgenic mouse brain, which models HD onset. We compared the
MGRN1 localization proﬁles in control and R6/2 mice. Immunoﬂuores-
cence staining showed that in control mice, MGRN1was predominantly
expressed in the cytoplasmic compartment of cerebellar Purkinje cells
and in cortical neurons. However, in R6/2 HD transgenic mice, MGRN1
was strongly recruited to neuronal p62-positive aggregates in cerebellar
Purkinje cells and in cortical neurons (Fig. 5A and B). To conﬁrm the
Fig. 3.MGRN1 associates with huntingtin expanded polyglutamine aggregates and recruitment of MGRN1 to ataxin-3 aggregates. (A–B) Cos-7 cells were transiently transfected with
EGFP-HDQ23 (A) EGFP-HDQ74 (B) constructs and after 48 h of transfection, the cells were processed for immunoﬂuorescence staining for MGRN1 (red) and normal and expanded
polyglutamine expressions (green). (C–D) EGFP-HDQ23 (C) and EGFP-HDQ74 (D) expressing Cos-7 cells were transiently transfected with Myc-MGRN1 plasmid. Thirty-six hours after
transfection, cells were subjected to immunoﬂuorescence staining with anti-MGRN1 (red). A rhodamine-conjugated secondary antibody was used to label MGRN1. Arrows indicate
the recruitment of MGRN1 to the huntingtin aggregates. (E–F) Cos-7 cells were transiently transfected with ataxin-3-GFP fusion normal (E) (ataxin-3(Q28)) and expanded
(F) polyglutamine (ataxin-3(Q84)) constructs. Post transfected cells were subjected to immunoﬂuorescence staining for MGRN1 (red) and normal and expanded polyglutamine expres-
sions (green). (G–H) Sub-conﬂuent Cos-7 cellswere plated into 2-well chamber slides and co-transfectedwith ataxin-3-GFP fusion constructs containing (ataxin-3(Q28)) (G) and (ataxin-
3(Q84)) (H) polyglutamine constructs along with Myc-MGRN1 plasmid as indicated. After transfection, the cells were ﬁxed in 4% paraformaldehyde and then processed for immunoﬂu-
orescencewith MGRN1 antibody. MGRN1 was visualized with rhodamine-conjugated secondary antibody (red). Arrows indicate the recruitment of MGRN1 to ataxin-3 aggregates. Scale
bar, 20 μm.
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the R6/2 HD mouse model, we performed double-immunoﬂuorescence
staining studies using MGRN1 and ubiquitin antibodies. Analysis of
these results showed that more than 70%–80% of the ubiquitin positive
aggregates were co-localized and recruited with the MGRN1 protein in
the different brain regions of the HD R6/2 transgenic mouse model
(Fig. 6A and B). We further conﬁrmed that these neuronal (NeuN) pos-
itive aggregates (Fig. 7A and B) were also positive for huntingtin stain-
ing and colocalize with MGRN1 and p62 inclusions in R6/2 transgenic
mice brain (Fig. 7C and D). We further performed the quantiﬁcation of
same samples and observed that the normal MGRN1 bearing neurons
were decreased in HD R6/2 transgenic mouse model (Fig. 7E and F).
3.5. MGRN1 promotes the ubiquitination of polyglutamine-expanded
proteins
The overburden ormassive production ofmisfoldedproteins can im-
pair the ubiquitin proteasome system [36]. To avoid such a drastic prob-
lem and to promote the clearance of toxic soluble misfolded
intermediates, cells adopt another strategy, i.e., autophagy-mediated
clearance [37]. In the current study, we noticed the deregulation and
strong association of MGRN1 with expanded polyglutamine proteins,
and therefore we posed the question: how does MGRN1 respond to ex-
panded polyglutamine proteins and target them for elimination? We
co-expressed truncated N-terminal huntingtin (EGFP-HDQ74) with
wild-type MGRN1 or its catalytic inactive mutant MGRN1 (AVVA)form. As shown in Fig. 8A, we observed that the overexpression of the
wild-type MGRN1 promotes the ubiquitination of EGFP-HDQ74
polyglutamine intermediates. To conﬁrm this ﬁnding, we precipitated
cell lysates from various experiments with GFP antibody, and blots
were probed using an anti-ubiquitin antibody. We speculated that
MGRN1 interaction with expanded polyglutamine proteins could in-
duce their ubiquitination. To validate this assumptionwe processed im-
munoprecipitation in cells expressing expanded polyglutamine
proteins using GFP antibody and blots were probed with ubiquitin anti-
body. Cell lysates obtained from expandedpolyglutamine proteinswere
centrifuged at 10,000 ×g at room temperature for 5 min and the sepa-
rated pellet and supernatant fractions were analyzed by immunoblot-
ting with antibodies against GFP and MGRN1. In pellet samples, higher
molecular protein complex of expanded polyglutamine proteins
retained in stacking gel (Fig. 8B). As shown in Fig. 8C, overexpression
of wild-type MGRN1 caused a signiﬁcant increase in the accumulation
of ubiquitinated derivatives of EGFP-HDQ74 proteins. Baﬁlomycin, an
autophagy inhibitor, also induces the accumulation of ubiquitinated
EGFP-HDQ74 proteins (Fig. 8C, left panel). Baﬁlomycin treatment
caused massive aggregate formation and the accumulation of high-
molecular-weight complexes of the expanded polyglutamine proteins,
which suggests that polyglutamine aggregation is also cleared by the
autophagy pathway (Fig. 8C, upper panel). As earlier reported,
MGRN1 enhances the proteasome-independent ubiquitination of
tumor-susceptibility gene101 (TSG101) [38]. ITCH is another E3 ubiqui-
tin ligase, which induces the degradation of Deltex (DTX) via lysosomal
Fig. 4.MGRN1 co-localization with huntingtin expanded-polyglutamine p62 and ubiquitin-positive aggregates in cells. (A) Cos-7 cells were transiently co-transfected with EGFP-HDQ74
construct andMyc-MGRN1 plasmid. After 48 h of transfection, the cells were subjected to triple-immunoﬂuorescence staining forMGRN1 (red), p62 (blue) and EGFP-HDQ74 expressions
(green) as described in the “experimental procedure”. Arrows indicate the recruitment of MGRN1 to huntingtin expanded-polyglutamine aggregates that are positive for p62 staining.
Scale bar, 20 μm. (B) As described above, some cells were subjected to triple-immunoﬂuorescence staining for MGRN1 (red), ubiquitin (blue) and EGFP-HDQ74 expressions (green).
The arrows indicate the co-localization of ubiquitin-positive huntingtin expanded-polyglutamine aggregates and MGRN1. Scale bar, 20 μm.
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ronal precursor cell-expressed, developmentally down-regulated
gene 4) is a HECT-domain ubiquitin ligase, which enhances the degrada-
tion of α-synuclein by the endo-lysosomal pathway [40]. These studies
also support our hypothesis that probably MGRN1 can promote the
ubiquitination of expanded polyglutamine through the autophagy path-
way. As shown in Fig. 8D and E, transiently transfected overexpressed
wild-type MGRN1 overexpression decreases the levels of EGFP-HDQ74
expanded polyglutamine proteins, which can be prevented upon the ad-
dition of the autophagy inhibitor baﬁlomycin (Fig. 8F andG). Earlier it has
been shown that improper sequestration of MGRN1 with cytosolic prion
proteins contributes in neurodegeneration and MGRN1 interacts with
Hsp70 chaperone [25,41]. Therefore it may be possible that MGRN1 tar-
gets expanded polyglutamine proteins anchored with Hsp70 chaperone
and promotes their clearance from the dense cellular pool, however for
better understanding in near future it needs further study in detail.3.6. MGRN1 suppresses aggregate formation and polyglutamine-induced
cell death
Because we observed that MGRN1 enhances the ubiquitination
and elimination of expanded polyglutamine proteins, we wondered
whether MGRN1 could affect polyglutamine protein aggregation
and polyglutamine protein-induced cell death. Therefore, we co-
transfected 293T cells with huntingtin (EGFP-HDQ74) and MGRN1 or
MGRN1-siRNA. As shown in Fig. 9A, aggregate formationwas decreased
by the overexpression of MGRN1. However, the number of aggregates
increased in cells transfected with MGRN1-siRNA. The overexpressionof MGRN1 enhances the clearance of expanded polyglutamine proteins,
and downregulation promotes the accumulation of polyglutamine pro-
teins (Fig. 9B). The overexpression of MGRN1 signiﬁcantly suppresses
aggregate formation in a concentration-dependentmanner (Fig. 9C). In-
terestingly, the suppression of aggregate formation and cytoprotective
affect against ER and heat stress was more pronounced when MGRN1
was overexpressed along with Hsp70 (Fig. 9E and G). Quantitative
data from cells transfected with MGRN1-siRNA in a concentration-
dependent manner showed a dose-dependent increase in the rate of
aggregate formation, conﬁrming the effect of MGRN1 on polyglutamine
aggregate formation (Fig. 9D). The knockdown of the endogenous levels
of MGRN1 also signiﬁcantly induced death in polyglutamine (74Q)-
expressing cells (Fig. 9F). We further conﬁrm the cumulative
cytoprotective role of MGRN1 and Hsp70 under various stress condi-
tions; therefore we exposed cells with ER and heat stress conditions
and observed that Hsp70 overexpression alleviates cytotoxicity under
different stress conditions (Fig. 9G). Taken together, our data suggest
that MGRN1 reduces the formation of aggregates of expanded
polyglutamine proteins and protects cells from death mediated by the
proteotoxic effects of polyglutamine proteins.4. Discussion
Cells eliminate abnormal proteins with the help of a protein quality
control mechanism (QC). Expanded polyglutamine proteins induced
multifactorial deleterious events in cells. Numerous E3s, such as Gp78,
E6-AP, CHIP, Parkin, Hrd1 andMalin, play a crucial role in the clearance
of polyglutamine proteins, reducing their aggregate formation and
Fig. 5. Redistribution and association of MGRN1 with p62-positive aggregates in R6/2
transgenic mice. (A–B) Immunoﬂuorescence double-labeling of MGRN1 and p62 in the
brain of R6/2 mouse. Adult mouse brain sections of the cerebellum (A) and cortex
(B) from control and R6/2 mice were incubated with p62 (green) and MGRN1 (red) anti-
bodies. In the overlay (yellow) image, arrows indicate the aggregates of the expanded
huntingtin that co-localize with p62 and MGRN1 with DAPI (blue) staining. Merging
(yellow) illustrates co-localization of MGRN1 and p62 in the inclusions. Scale bar, 20 μm.
Fig. 6. Co-localization of MGRN1 with ubiquitin-positive aggregates in the neurons of the
transgenic R6/2 mouse model of Huntington's disease. (A–B) Sections from the adult
mouse brain subjected to immunoﬂuorescence staining with anti-ubiquitin and anti-
MGRN1 in the cerebellum (A) and cortex (B) of control and R6/2 transgenic mice. The
FITC-conjugated secondary antibody was used to label the ubiquitin, and rhodamine-
conjugated secondary antibodywas used to stainMGRN1. Arrows indicate the aggregates
of expanded huntingtin that co-localize with MGRN1 and ubiquitin. The overlay images
also show DAPI staining of the cell nuclei. Scale bar, 20 μm.
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that mahogunin ring ﬁnger-1 (MGRN1), a putative E3 ubiquitin ligase,
interacts with misfolded and ubiquitinated expanded polyglutamine
proteins in a cellular model of HD. Additionally, we observed the re-
cruitment and co-localization of MGRN1 ubiquitin ligase in various
brain regions in the R6/2 transgenic mouse model of HD. Finally, we
showed that overexpression of MGRN1 facilitates the elimination of
misfolded polyglutamine proteins via autophagy and reduces aggregate
formation and cell death in expanded polyglutamine-expressing cells.
The overburden of misfolded or non-native protein aggregation im-
pairs the function of the ubiquitin proteasome system [36,46]. However,
how the accumulation or aggregation of polyglutamineproteins impairs
the function of the ubiquitin proteasome system and contributes to the
pathomechanism of the disease is still controversial [47–51]. Previous
studies indicate that the aggregation of polyglutamine proteins signiﬁ-
cantly impairs the activity of the proteasome against stress-induced
protein aggregation [27,52]. However, we do not know how cells sur-
vive the proteasome dysfunction caused bymassive polyglutamine pro-
tein aggregation. Thus, it is important to understandwhat other cellular
factors or pathways are involved in cell survival and the mechanisms
that inhibit polyglutamine-mediated cellular toxicity. Reports suggest
that to avoid these noxious conditions and to eliminate the misfolded
protein load, the cellular protein quality control mechanism (QC)
adopts another survival strategy, i.e., autophagy-mediated clearance
[37,53,54]. Neural precursor cells that express both developmentally
downregulated protein 4 (NEDD4) and atrophin-interacting protein 4
(AIP4)/Itch E3 ubiquitin ligases promote the clearance of melanocytictransmembrane proteins (i.e., Melan-A/MART-1) by lysosomes [55].
MGRN1 is a ring ﬁnger-1 E3 ubiquitin ligase that is involved in
spongiform neurodegeneration encephalopathy. Recently it has been
observed that MGRN1 overexpression and loss of function do not inﬂu-
ence prion disease; possibly functional sequestration of MGRN1 may
cause cytosolic PrP linked neurotoxicity [56]. We have shown that
MGRN1 overexpression reduces the aggregation of chaperone associat-
edmisfolded proteins in cells [41]. MGRN1 facilitates the ubiquitination
and degradation of tumor-susceptibility gene 101 (TSG101) via the
endolysosomal pathway [57].
Earlier it has been proposed that cytosolic prion protein exposure
disrupts the function of MGRN1 that contributes in neurodegeneration
[25]. In our current study we have also observed that MGRN1 mRNA
and protein levels were reduced in the poly (Q) expanded huntingtin-
and ataxin-3 fragment-expressing cells. Why were endogenous
MGRN1 levels depleted in polyglutamine-expressing cells? Previous
studies elaborate that the interaction of polyglutamine aggregates inter-
rupts the normal function of various transcription factors such as nucle-
ar factor kappa-light-chain-enhancer of activated B cells (NF-κB), CREB
binding protein (CBP), TATA box binding protein (TBP) and speciﬁcity
protein 1 (Sp1) [58–62]. Most probably sequestration and depleted
function of these transcriptions contribute in the molecular
pathomechanism of polyglutamine diseases. Overall these studies also
support our current speculation that MGRN1 interacts with
polyglutamine aggregated intermediate species for their clearance. It
is possible that this interaction leads to the co-aggregation and
Fig. 7. Recruitment of p62 andMGRN1with huntingtin-positive aggregates in the neurons of the transgenic R6/2mousemodel of Huntington's disease. (A–B) Brain sections of R6/2mice
were immunostained for NeuN (green) andMGRN1 (red) in cortex (A) and cerebellum (B) regions. The FITC-conjugated secondary antibodywas used to label the NeuN, and rhodamine-
conjugated secondary antibody was used to stain MGRN1. Arrows indicate MGRN1-positive aggregates in the neurons. (C) Sections from the adult mouse brain processed to immunoﬂu-
orescence staining with anti-huntingtin and MGRN1 antibody in the control and R6/2 transgenic mice. The FITC-conjugated secondary antibody was used to label the huntingtin, and
rhodamine-conjugated secondary antibody was used to stain MGRN1. Arrows indicate the aggregates of expanded huntingtin that co-localize with MGRN1. (D) Double immunoﬂuores-
cence staining of p62 and huntingtin in the brain of an R6/2mouse. Adultmouse brain sections from control and R6/2micewere probedwith huntingtin (green) and p62 (red) antibodies.
In the overlay (yellow) image, arrows indicate the aggregates of the expanded huntingtin that co-localize with p62 staining. Merging (yellow) illustrates co-localization of MGRN1 and
huntingtin in the inclusions. Scale bar, 20 μm. (E) Percentage of neurons with normal MGRN1 staining per total cortical neurons from B6. (F) Quantitative analysis of p62, ubiquitin
and MGRN1 positive inclusions in the HD transgenic mice brain sections along with their age-matched control.
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Fig. 8.MGRN1 overexpression induces the ubiquitination of polyglutamine-expanded proteins. (A) Cos-7 cells were transiently co-transfected with MGRN1-GFP and EGFP-HDQ74 con-
structs. After 48 h, the cells were subjected to immunoblotting analysis by using anti-ubiquitin, anti-GFP and anti-actin. (B) Cells were transfected with normal (EGFP-HDQ23) and
polyglutamine-expanded (EGFP-HDQ74) constructs and lysates were processed for IP by GFP antibody and blot was developed with anti-ubiquitin. Cell lysates obtained from expanded
polyglutamine proteinswere separated in supernatant and pellet fractions and performed immunoblottingwith anti-GFP and anti-MGRN1 antibodies (B). (C) The same cells were treated
with orwithout 50 nMbaﬁlomycin (Baf) for 12 h and subjected to immunoblotting analysiswith GFP antibody. Some cells were co-transfectedwithMGRN1 (AVVA)-GFPmutant plasmid
and the EGFP-HDQ74 construct. Cell lysates were subjected to immunoprecipitation (IP) using GFP antibody, and blots were probed with GFP, ubiquitin and actin antibodies. (D) Cos-7
cells were transiently co-transfected with EGFP-HDQ23 and EGFP-HDQ74 constructs with MGRN1. At 48 h after transfection, the cells were treated with cycloheximide (15 μg/ml) and
chased for different periods. Blots were detected with GFP and actin antibodies. (E) Quantitation of the blot band intensities from three independent experiments was performed using
NIH Image analysis software. Values are the mean ± SD. (F) As described in C plus treatment with 50 nM baﬁlomycin (Baf). Blots were detected with GFP and actin antibodies.
(G) The line graph shows the quantitation of the blot band intensities from three independent experiments performed using NIH Image analysis software. Values are the mean ± SD.
*, p b 0.05 compared with control.
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aggregates, and this prolonged mislocalization may lead to the de-
pletion of MGRN1, most likely contributing to the pathogenesis of
polyglutamine diseases. In the present study, we conﬁrmed the interac-
tion of MGRN1with expanded polyglutamine proteins via a detailed co-
immunoprecipitation study and observed the co-localization of MGRN1
with cellular aggregates of poly (Q) expanded huntingtin and ataxin-3
protein. Previously, malin E3 ubiquitin ligase was shown to associate
with ubiquitinated Lafora bodies, and the loss of malin function most
likely contributes to the pathogenesis of Lafora disease [63]. The malin
E3 ubiquitin ligase study supports our current ﬁndings; to validate this
novel interaction, we used triple-immunoﬂuorescence analysis and re-
port the co-localization of MGRN1 with p62 and ubiquitin-positive
polyglutamine aggregates in cells.
Based on the interaction and co-localization ofMGRN1with expand-
ed polyglutamine proteins in the cellular model of HD disease, we ob-
served the recruitment of MGRN1 to the neuronal aggregates in R6/2
transgenicmice. In thismousemodel of HDdisease, wewere able to de-
tect a signiﬁcant number of aggregates that were positive for MGRN1,
p62 and ubiquitin staining and a clear redistribution of MGRN1 from
the cytoplasm to the aggregates in the cerebellar Purkinje cells and cor-
tical neurons. These results prompted us to investigate the functional
role of MGRN1 in the elimination of expanded polyglutamine proteins
and the consequent effect of this degradation on aggregate formation.
We showed that autophagy inhibition induces the ubiquitination of ex-
panded polyglutamine proteins. Induced autophagy retains an ability to
reduce the toxicity of expanded polyglutamine proteins [64]. Our obser-
vations demonstrated that MGRN1 overexpression speciﬁcally stimu-
lates the rate of degradation of the polyglutamine protein expansions
and reduces aggregate formation, providing a cytoprotective responseagainst polyglutamine-induced toxicity. This result was conﬁrmed by
the depletion of MGRN1 levels by siRNA, which increased the accumu-
lation of expanded polyglutamine protein aggregates and enhanced
the poly (Q) expansion-induced cell death. Interestingly, we noted
that the protective response was more prominent when MGRN1 and
the Hsp70 chaperone were co-expressed.
The identiﬁcation of an E3 ubiquitin ligase that is capable of elimi-
natingmisfolded aggregated proteins represents a potential therapeutic
approach against diseases caused by disordered proteins. There are
numerous studies implicating autophagy or selective autophagy in
polyglutamine diseases [65–67]. However, the detailed molecular
function of autophagy in the selective recognition of expanded
polyglutamine proteins is still not well understood. Our current study
indicates that the recruitment of MGRN1with expanded polyglutamine
proteins occurs in cellular and mouse models of HD disease. Together,
our results suggest thatMGRN1 interacts with expanded polyglutamine
proteins; the association of MGRN1 promotes the ubiquitination and
elimination of poly (Q) expansions that eventually alleviate aggregation
and cell death. MGRN1 provides cytoprotection against polyglutamine
induced toxicity and probably its aberrant function plays a crucial role
in the pathomechanism of neurodegeneration and possibly holds ther-
apeutic potential for treating protein-disordered diseases.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.04.014.
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